Insider Trading April 16, 2026 06:55 PM

Astera Labs CEO Disposes $518K in Stock Under 10b5-1 Plan

Jitendra Mohan sold 2,967 shares on April 15, 2026; company also reported a strong Q4 2025 earnings beat

By Jordan Park ALAB
Astera Labs CEO Disposes $518K in Stock Under 10b5-1 Plan
ALAB

Astera Labs Chief Executive Officer Jitendra Mohan executed planned sales of company stock on April 15, 2026, generating roughly $518,036 in proceeds. The transactions were completed under a pre-arranged 10b5-1 plan and occurred while ALAB shares have risen substantially over the past year. Separately, the company reported a fourth-quarter 2025 earnings beat and double-digit revenue growth.

Key Points

  • CEO Jitendra Mohan sold 2,967 shares on April 15, 2026, under a pre-arranged 10b5-1 plan, generating about $518,036 in proceeds.
  • Astera Labs shares are trading at $170.81 and have risen 191% over the last year, while InvestingPro analysis flags the stock as overvalued relative to its Fair Value.
  • Astera Labs reported Q4 2025 results with EPS of $0.58 versus a $0.51 estimate and revenue of $270.6 million, a 92% year-over-year increase.

Astera Labs, Inc. (NASDAQ: ALAB) reported an insider sale by Chief Executive Officer Jitendra Mohan on April 15, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filing shows Mohan sold a total of 2,967 shares of common stock under a pre-arranged 10b5-1 trading plan, generating approximately $518,036 in proceeds.

The disposition was split into two distinct transactions. The larger tranche consisted of 2,767 shares sold at a weighted average price of $174.5682, with trade prices in that block ranging from $174.00 to $174.91. A second, smaller sale recorded 200 shares at $175.03.

The insider sales took place while ALAB shares were trading at $170.81. The stock has delivered a notable 191% gain over the past 12 months. An InvestingPro analysis cited in the filing states that the shares appear overvalued relative to the platform's Fair Value estimate and ranks ALAB among the most overvalued names tracked by that service.

After the reported transactions, the ownership disclosed in the filing shows Mohan retains a substantial position across direct and indirect holdings. He continues to indirectly hold 4,405,015 shares through a living trust, an additional 6,350,002 shares indirectly through several other trusts, and directly holds 1,452,739 shares.


Investors seeking additional valuation and performance data are directed to the comprehensive Pro Research Report available for this company and more than 1,400 other U.S. equities on InvestingPro.

In separate corporate disclosures, Astera Labs reported strong fourth-quarter 2025 financial results that exceeded analyst expectations. The company posted earnings per share of $0.58, beating the $0.51 estimate by 13.73%. Revenue for the quarter came in at $270.6 million, a 92% increase year-over-year. The company noted an after-hours uptick in its share price following those results; this article concentrates on the reported earnings and revenue figures.


The Form 4 filing and the quarterly results together offer a snapshot of recent executive activity and company performance. The insider sale was executed under a standing trading plan, and public filings indicate that Mohan remains a significant shareholder across direct and trust-held positions.

Risks

  • The insider sale was executed under a pre-arranged 10b5-1 plan; the presence of such plans can limit the interpretability of timing and motivation behind executive trades - this affects investor perception in the equities and corporate governance sectors.
  • InvestingPro analysis indicates ALAB is overvalued relative to its Fair Value, which may signal valuation risk for equity investors in the technology and semiconductor supply chain sectors.
  • The article focuses on reported earnings and revenue but does not provide forward guidance or other operational detail, leaving uncertainties for investors evaluating future performance in financial markets.

More from Insider Trading

GrabAGun CEO Sells Shares to Cover RSU Taxes as Stock Trades Near 52-Week Low Apr 16, 2026 GrabAGun Digital CFO Disposes of 2,043 Shares to Cover RSU Tax Withholding Apr 16, 2026 Tango Therapeutics R&D President Sells $961,500 in Stock After Exercising Options Apr 16, 2026 GrabAGun Digital COO Sells Small Stake to Cover RSU Taxes as Shares Hover Near 52-Week Low Apr 16, 2026 Klaviyo Co-CEO Sells $3.4M in Shares, Converts Stock Amid Buyback and Product Moves Apr 16, 2026